5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome : A Randomized Clinical Trial

      research-article
      , MD, PhD 1 , 2 , , , PhD 2 , 3 , , MD 2 , , MD 2 , , MSc 2 , , MSc 2 , , MD 2 , , MD 4 , , MD 5 , , MD 6 , , MD 7 , , MD 8 , , MD 9 , , MD 10 , , MD 11 , , MD 12 , , MD 13 , , MD 14 , , MD 15 , , MD 16 , , MD 17 , , MD 18 , , MD 19 , , MD 20 , , MD 21 , , MD 22 , , MD 23 , , MD 24 , , MD 25 , , PhD 26 , 27 , 28 , , PhD 29 , , MD 30 , , MD 31 , , MD 2 , 32 , , PhD 33
      JAMA
      American Medical Association

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          Does acupuncture alone or combined with clomiphene increase the likelihood of live births among women with polycystic ovary syndrome?

          Findings

          In this randomized clinical trial that recruited 1000 Chinese women with polycystic ovary syndrome, the live birth rate was significantly higher in the group of women who received clomiphene compared with placebo (28.7% vs 15.4%, respectively). However, it was not significantly different between the groups who received active vs control acupuncture (21.8% vs 22.4%, respectively), and there was no significant interaction between active acupuncture and clomiphene.

          Meaning

          Acupuncture, alone or with clomiphene, was not effective as an infertility treatment in women with polycystic ovary syndrome.

          Abstract

          This 2 × 2 factorial trial compared the effects of active vs sham acupuncture and of clomiphene vs placebo on live births among Chinese women with polycystic ovary syndrome (PCOS).

          Abstract

          Importance

          Acupuncture is used to induce ovulation in some women with polycystic ovary syndrome, without supporting clinical evidence.

          Objective

          To assess whether active acupuncture, either alone or combined with clomiphene, increases the likelihood of live births among women with polycystic ovary syndrome.

          Design, Setting, and Participants

          A double-blind (clomiphene vs placebo), single-blind (active vs control acupuncture) factorial trial was conducted at 21 sites (27 hospitals) in mainland China between July 6, 2012, and November 18, 2014, with 10 months of pregnancy follow-up until October 7, 2015. Chinese women with polycystic ovary syndrome were randomized in a 1:1:1:1 ratio to 4 groups.

          Interventions

          Active or control acupuncture administered twice a week for 30 minutes per treatment and clomiphene or placebo administered for 5 days per cycle, for up to 4 cycles. The active acupuncture group received deep needle insertion with combined manual and low-frequency electrical stimulation; the control acupuncture group received superficial needle insertion, no manual stimulation, and mock electricity.

          Main Outcomes and Measures

          The primary outcome was live birth. Secondary outcomes included adverse events.

          Results

          Among the 1000 randomized women (mean [SD] age, 27.9 [3.3] years; mean [SD] body mass index, 24.2 [4.3]), 250 were randomized to each group; a total of 926 women (92.6%) completed the trial. Live births occurred in 69 of 235 women (29.4%) in the active acupuncture plus clomiphene group, 66 of 236 (28.0%) in the control acupuncture plus clomiphene group, 31 of 223 (13.9%) in the active acupuncture plus placebo group, and 39 of 232 (16.8%) in the control acupuncture plus placebo group. There was no significant interaction between active acupuncture and clomiphene ( P = .39), so main effects were evaluated. The live birth rate was significantly higher in the women treated with clomiphene than with placebo (135 of 471 [28.7%] vs 70 of 455 [15.4%], respectively; difference, 13.3%; 95% CI, 8.0% to 18.5%) and not significantly different between women treated with active vs control acupuncture (100 of 458 [21.8%] vs 105 of 468 [22.4%], respectively; difference, −0.6%; 95% CI, −5.9% to 4.7%). Diarrhea and bruising were more common in patients receiving active acupuncture than control acupuncture (diarrhea: 25 of 500 [5.0%] vs 8 of 500 [1.6%], respectively; difference, 3.4%; 95% CI, 1.2% to 5.6%; bruising: 37 of 500 [7.4%] vs 9 of 500 [1.8%], respectively; difference, 5.6%; 95% CI, 3.0% to 8.2%).

          Conclusions and Relevance

          Among Chinese women with polycystic ovary syndrome, the use of acupuncture with or without clomiphene, compared with control acupuncture and placebo, did not increase live births. This finding does not support acupuncture as an infertility treatment in such women.

          Trial Registration

          clinicaltrials.gov Identifier: NCT01573858

          Related collections

          Author and article information

          Journal
          JAMA
          JAMA
          JAMA
          JAMA
          American Medical Association
          0098-7484
          1538-3598
          27 June 2017
          27 June 2017
          27 December 2017
          : 317
          : 24
          : 2502-2514
          Affiliations
          [1 ]Committee of Reproductive Medicine, World Federation of Chinese Medicine Societies, Beijing, China
          [2 ]Department of Obstetrics and Gynecology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China
          [3 ]Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
          [4 ]Outpatient Department, Xuzhou Maternal and Children’s Hospital, Xuzhou, China
          [5 ]Centre for Reproductive Medicine, Dalian Maternal and Children’s Centre, Dalian, China
          [6 ]Department of Infertility, Tanggu District Maternal and Children’s Hospital, Tianjin, China
          [7 ]Department of Obstetrics and Gynecology, Shanxi Province Hospital of Chinese Medicine, Taiyuan, China
          [8 ]Centre for Reproductive Medicine, Huaian Maternal and Children’s Hospital, Huaian, China
          [9 ]Department of Gynecology, Suzhou City Hospital of Chinese Medicine, Suzhou, China
          [10 ]Department of Gynecology, Second Hospital, Jiangxi University of Chinese Medicine, Nanchang, China
          [11 ]Department of Chinese Medicine, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
          [12 ]Department of Infertility, Liwan District Hospital of Chinese Medicine, Guangzhou, China
          [13 ]Department of Obstetrics and Gynecology, Affiliated Hospital, Anhui University of Chinese Medicine, Hefei, China
          [14 ]Institute of Integrated Traditional and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
          [15 ]Department of Gynecology, Wenzhou City Hospital of Chinese Medicine, Wenzhou, China
          [16 ]Centre for Reproductive Medicine, Yuhuangding Hospital, Yantai, China
          [17 ]Department of Obstetrics and Gynecology, Daqing Longnan Hospital, Daqing, China
          [18 ]Department of Obstetrics and Gynecology, First Affiliated Hospital, Hunan University of Chinese Medicine, Changsha, China
          [19 ]Department of Obstetrics and Gynecology, First Affiliated Hospital, Liaoning University of Chinese Medicine, Shenyang, China
          [20 ]Department of Gynecology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
          [21 ]Department of Traditional Technology, Guangdong Province Hospital of Chinese Medicine, Guangzhou, China
          [22 ]Department of Gynecology, Hangzhou City Hospital of Chinese Medicine, Hangzhou, China
          [23 ]Centre for Reproductive Medicine, Zhejiang Province Hospital of Integrative Medicine, Hangzhou, China
          [24 ]Centre for Reproductive Medicine, Daqing Oilfield General Hospital, Daqing, China
          [25 ]Department of Obstetrics and Gynecology, Hubei Province Hospital of Chinese Medicine, Wuhan, China
          [26 ]Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, China
          [27 ]Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China
          [28 ]School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China
          [29 ]Chinese Clinical Trial Registry, Shenzhen, China
          [30 ]Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
          [31 ]Department of Obstetrics and Gynecology, The University of Hong Kong, Hong Kong, China
          [32 ]Department of Obstetrics and Gynecology, Pennsylvania State University, Hershey
          [33 ]Department of Biostatistics, Yale University School of Public Health, New Haven, Connecticut
          Author notes
          Article Information
          Group Information: The PCOSAct Study Group members are listed at the end of this article.
          Corresponding Author: Xiao-Ke Wu, MD, PhD, Department of Obstetrics and Gynecology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin 150040, China ( xiaokewu2002@ 123456vip.sina.com ).
          Accepted for Publication: May 24, 2017.
          Author Contributions: Dr X.-K. Wu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs X.-K. Wu and Stener-Victorin share first authorship. Drs X.-K. Wu and H. Zhang contributed equally to this work.
          Concept and design: X.-K. Wu, Stener-Victorin, T.-X. Wu, Liu, Ng, Legro, H. Zhang.
          Acquisition, analysis, or interpretation of data: X.-K. Wu, Stener-Victorin, Kuang, H.-L. Ma, J.-S. Gao, Xie, Hou, Hu, Shao, Ge, J.-F. Zhang, Xue, Xu, Liang, H.-X. Ma, H.-W. Yang, Li, Huang, Sun, Hao, Du, Z.-W. Yang, X. Wang, Yan, Chen, Fu, Ding, Y.-Q. Gao, Zhou, C. C. Wang, Ng, Legro, H. Zhang.
          Drafting of the manuscript: X.-K. Wu, Stener-Victorin, H.-L. Ma, H. Zhang.
          Critical revision of the manuscript for important intellectual content: X.-K. Wu, Stener-Victorin, Kuang, H.-L. Ma, J.-S. Gao, Xie, Hou, Hu, Shao, Ge, J.-F. Zhang, Xue, Xu, Liang, H.-X. Ma, H.-W. Yang, Li, Huang, Sun, Hao, Du, Z.-W. Yang, X. Wang, Yan, Chen, Fu, Ding, Y.-Q. Gao, Zhou, C. C. Wang, T.-X. Wu, Liu, Ng, Legro, H. Zhang.
          Statistical analysis: H.-L. Ma, Xie, H. Zhang.
          Obtained funding: X.-K. Wu.
          Administrative, technical, or material support: X.-K. Wu, Kuang, H.-L. Ma, J.-S. Gao, Hou, Hu, Shao, Ge, J.-F. Zhang, Xue, Xu, Liang, H.-X. Ma, H.-W. Yang, Li, Huang, Sun, Hao, Du, Z.-W. Yang, X. Wang, Yan, Chen, Fu, Ding, Y.-Q. Gao, Zhou, C. C. Wang, T.-X. Wu.
          Supervision: X.-K. Wu, Stener-Victorin, Liu, Ng, Legro, H. Zhang.
          Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Legro reported serving as a consultant to Bayer, Kindex, Euroscreen, Millendo, Takeda, Clarus, Sprout, and AstraZeneca; serving as a site investigator and receiving grants from Ferring; and receiving grants from AstraZeneca. No other disclosures were reported.
          Funding/Support: This work was supported by grants 201107005 and 200807002 from the National Public Welfare Projects for Chinese Medicine, JC200804 from the Heilongjiang Province Foundation for Outstanding Youths, 2011TD006 from the Intervention for PCOS Based on Traditional Chinese Medicine Theory–TianGui Disorder, and JDZX2012036 and 2015B009 from 2009 through 2016 at the First Affiliated Hospital, Heilongjiang University of Chinese Medicine from the National Clinical Trial Base in Chinese Medicine Special Projects, by the National Key Discipline of Chinese Medicine in Gynecology from 2009 through 2016, by the Heilongjiang Province “Longjiang Scholar” Program (Drs X.-K. Wu, Stener-Victorin, and Legro), and by the Chinese “Thousand Talents Plan” scholarship (Drs Legro and H. Zhang).
          Role of the Funder/Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
          Group Information: The PCOSAct Study Group includes the authors plus the following individuals who contributed to data collection at local sites: Jin-Ying Fu, MD, Henan Province Hospital of Chinese Medicine, Zhengzhou, China; Chang-Ling Zhu, MD, Wenzhou Zhongshan Hospital, Wenzhou, China; Xiao-Hong Wang, MD, Xuzhou City Hospital of Chinese Medicine, Xuzhou, China; Yang Xia, MD, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China; Yan-Qiu Du, MD, Daqing Longnan Hospital, Daqing, China; and Hui-Fang Cong, MD, Second Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China. The following individuals contributed to administrative resource supports: Song-Jiang Liu, MD, and Gui-Yuan Wang, MSc, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China; Shu-Lai Li, MD, Tanggu District Maternal and Children’s Hospital, Tianjin, China; Ke-Qiu Zhang, MD, Xuzhou Maternity and Children’s Hospital, Xuzhou, China; and Jian-Hua Shen, MD, Liwan District Hospital of Chinese Medicine, Guangzhou, China.
          Additional Contributions: Data and safety monitoring board members of this trial included Robert W. Rebar, MD (chair), American Society for Reproductive Medicine, Birmingham, Alabama; Esther Eisenberg, MD, Vanderbilt University Medical Center, Nashville, Tennessee; Wei-Liang Weng, MD, China Academy of Traditional Chinese Medicine, Beijing, China; Su-Lun Sun, Beijing University of Chinese Medicine, Beijing, China; Wei Zou, MD, Heilongjiang University of Chinese Medicine, Harbin, China; and Zi-Dan Chen, MSc, China University of Mining and Technology, Beijing, China. They ensured the safety of study patients and the integrity of the research data independently; they received consulting fees. We thank the Reproductive Medicine Network Steering Committee of the National Institutes of Health for sharing the protocol and case report forms from the Pregnancy in Polycystic Ovary Syndrome II study.
          Article
          PMC5815063 PMC5815063 5815063 joi170062
          10.1001/jama.2017.7217
          5815063
          28655015
          b2390bac-8378-41f3-961a-1275af759f10
          Copyright 2017 American Medical Association. All Rights Reserved.
          History
          : 27 November 2016
          : 17 May 2017
          : 24 May 2017
          Funding
          Funded by: National Public Welfare Projects for Chinese Medicine
          Funded by: Heilongjiang Province Foundation for Outstanding Youths
          Funded by: Intervention for PCOS Based on Traditional Chinese Medicine Theory–TianGui Disorder
          Funded by: National Clinical Trial Base in Chinese Medicine Special Projects
          Funded by: National Key Discipline of Chinese Medicine in Gynecology
          Funded by: Heilongjiang Province “Longjiang Scholar” Program
          Funded by: “Thousand Talents Plan”
          Categories
          Research
          Research
          Original Investigation

          Comments

          Comment on this article